Endocyte, Inc. (ECYT)

23.99
NASDAQ
Prev Close 23.99
Day Low/High 0.00 / 0.00
52 Wk Low/High 8.03 / 24.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Endocyte Reaches Analyst Target Price

Endocyte Reaches Analyst Target Price

In recent trading, shares of Endocyte Inc have crossed above the average analyst 12-month target price of $23.33, changing hands for $23.39/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Dow Dives Sharply on Rates Fears, Tech Shares Sink Nasdaq

Dow Dives Sharply on Rates Fears, Tech Shares Sink Nasdaq

Stocks fall sharply on Thursday after a hawkish set of minutes from last month's Federal Reserve meeting cements the case for near-term interest rate hikes.

Novartis Secures Prostate Cancer Treatment With Endocyte Deal

Novartis Secures Prostate Cancer Treatment With Endocyte Deal

The Swiss drugmaker will pay $2.1 billion for Endocyte, justifying the Nasdaq-listed biotech's pivot to prostate treatment last year.

Facebook, Fed Minutes, AmEx, PayPal and Endocyte - 5 Things You Must Know

Facebook, Fed Minutes, AmEx, PayPal and Endocyte - 5 Things You Must Know

U.S. stock futures decline after a hawkish set of minutes from last month's Federal Reserve meeting; American Express, PayPal and Travelers report earnings; Facebook believes hack was done by spammers, says a report; Novartis to buy Endocyte for $2.1 billion.

Market Acting Like the Worst Is Over

Market Acting Like the Worst Is Over

Stocks are following through on Friday's rebound for now.

Endocyte Nominates Dawn Svoronos For Election To Its Board Of Directors And Announces Other Board Developments

Endocyte Nominates Dawn Svoronos For Election To Its Board Of Directors And Announces Other Board Developments

Dawn Svoronos, Former President of Merck's Europe/Canada Region, Brings Significant Commercial Leadership and Board Experience

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years

Small-cap stocks have finally jumped back to life on prospects for a strong U.S. economy this year. What trade war?

First Week of ECYT October 19th Options Trading

First Week of ECYT October 19th Options Trading

Investors in Endocyte Inc saw new options begin trading this week, for the October 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Focused on Stock Picking Through This Volatility

Focused on Stock Picking Through This Volatility

I'm trying not to be sucked into the market-timing game and am looking mainly at setups in individual stocks.

Closing Bell; Endocyte Spikes: LIVE MARKETS BLOG

Closing Bell; Endocyte Spikes: LIVE MARKETS BLOG

A drug licensing agreement sent Endocyte skyrocketing.